Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097694 · ClinicalTrials.gov registry record · Phase 2
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT01097694 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 176 participants.
The verdict
NCT01097694, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.
Interventions
- DRUG Placebo
- DRUG Imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097694
The ClinicalTrials.gov registry entry for NCT01097694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01097694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097694 about?
NCT01097694 is a clinical study titled "Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)". The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.
What is the current status of trial NCT01097694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2010-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01097694?
The interventions under investigation include: Placebo (DRUG), Imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01097694?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.